Catalyst Pharmaceuticals (CPRX) - מזומנים למניה

Catalyst Pharmaceuticals generates revenue through the exclusive sale of Firdapse therapy for the treatment of a rare autoimmune syndrome. This cash per share chart from the GURU.Markets terminal contains data where the 6.23 mark represents the current metric. A dedicated staff of niche experts ensures stability, however, high dependence on a single product creates risks due to potential patent disputes or the emergence of low-cost generics.
פילוחי מדדים מקיפים ואנליטיקה עבור Catalyst Pharma (CPRX)

When assessing the financial stability of Catalyst Pharmaceuticals (CPRX), it is essential to understand that this indicator measures available liquidity per share, allowing for the determination of the actual capital cushion. By analyzing this cash per share chart, an investor can see a safety buffer that, for a monopolist in the treatment of Lambert-Eaton syndrome, complements high pricing power and guarantees stability in the absence of alternative medications.